Celltrion nabs emergency use for rapid COVID-19 test from FDA

Jung Jin Seo, chairman of Celltrion Group (Celltrion)

Celltrion has nabbed a speedy preapproval for its quick pandemic virus test as it forecasts high demand.

This comes three months after asking the FDA for an emergency use authorization, which has been giving COVID-19 tests and drugs the ability to be used in the U.S. but is not a full approval.

RELATED: Celltrion passes early safety trial for anti-COVID-19 antibody as key tests await

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Celltrion, better known for its drug biosimilars but now also working on an COVID-19 antibody, said in a statement that it “believes the demand for rapid diagnosis kits will be high, mainly among large businesses and government agencies that are about to return to work after telecommuting.”

It has named the test Sampinute; it can deliver results within 10 minutes and has, according to the South Korean company, a 94% sensitivity rate. Shares in the company jumped nearly 5% on the news Monday morning.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

Baxter has received clearance from the FDA for the latest version of its automated peritoneal dialysis system designed for home use.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.